Questions

1. ECG Abnormalities:
   • Pathologic, deep, and wide Q waves (width $\ge 0.03\text{ s}$, depth $> 3\text{–}4\text{ mm}$ or $> 25\%$ of the ensuing R-wave amplitude) in lateral leads (I, aVL, and $V_5\text{–}V_6$).
   • Marked ST-segment elevation or depression and T-wave inversion in lateral leads ($V_5\text{–}V_6$, I, aVL), signifying anterolateral transmural myocardial ischemia/infarction.
   • Diminished or absent R-wave progression across the precordial leads ($V_1\text{–}V_4$).
   • Evidence of left ventricular hypertrophy (LVH) or left atrial enlargement (P-mitrale) secondary to ischemic dilated cardiomyopathy.
2. Definitive Diagnosis:
   • Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA).
   • Eponym: Bland-White-Garland syndrome.
3. Pathophysiology of Presentation at 6–8 Weeks:
   • In utero and during the early neonatal period, high pulmonary vascular resistance (PVR) maintains high pulmonary arterial pressure, driving antegrade, relatively oxygenated blood flow into the anomalous left coronary artery.
   • Between 6 and 8 weeks of life, physiological decline in PVR reduces pulmonary arterial diastolic pressure below systemic coronary vascular resistance.
   • This causes reversal of flow in the left coronary artery (coronary steal phenomenon), shunting blood away from the high-resistance myocardial capillary bed directly into the low-pressure pulmonary trunk via intercoronary collaterals.
   • Severe left ventricular subendocardial and transmural ischemia develops, causing papillary muscle dysfunction (mitral regurgitation), left ventricular dilation, and heart failure.
4. Management Protocol:
   • Preoperative Medical Stabilization:
     • Furosemide: $1\text{ mg/kg/dose}$ IV q12h to relieve pulmonary congestion.
     • Milrinone: Loading dose omitted; continuous infusion at $0.25\text{–}0.75\ \mu\text{g/kg/min}$ IV for inotropic support and afterload reduction without increasing myocardial oxygen consumption.
     • Avoid high-concentration supplemental oxygen (keep target $SpO_2\ 92\text{–}95\%$) to prevent sudden pulmonary vasodilation which exacerbates coronary steal.
   • Definitive Surgical Repair:
     • Direct reimplantation of the anomalous left coronary artery button into the ascending aorta (coronary button transfer to re-establish a dual coronary arterial system).
     • If anatomically unfeasible due to distance from the aorta: Takeuchi procedure (intrapulmonary baffle tunnel creating an aortopulmonary window to the ostium of the anomalous left coronary artery).

Normal Neonatal PVR (High) -> Antegrade Left Coronary Perfusion (Myocardium Viable)
                │
                ▼ (6-8 Weeks of Life)
Physiological Fall in PVR -> Low Pulmonary Artery Diastolic Pressure
                │
                ▼
Left-to-Right Shunt via Intercoronary Collaterals ("Coronary Steal")
                │
                ▼
Anterolateral Transmural Ischemia -> Papillary Muscle Dysfunction -> Severe MR & Heart Failure

1. Primary Diagnosis:
   • Premature Atrial Contraction (PAC) / Atrial ectopic beat with an incomplete (non-compensatory) pause.
2. Differentiation from Premature Ventricular Complex (PVC):
   • P wave: Present in PAC (premature, abnormal contour or axis compared to sinus P wave, often hidden within the preceding T wave); absent before a PVC (or retrogradely conducted after the QRS).
   • QRS complex duration: Narrow and identical to sinus beats in PAC ($< 0.08\text{ s}$ in children), unless conducted with aberration; wide and bizarre in PVC ($\ge 0.09\text{–}0.10\text{ s}$) with discordant T-wave morphology.
   • Pause characteristics: Incomplete/non-compensatory pause in PAC (sinus node is reset by the ectopic impulse); complete compensatory pause in PVC (sinus node cadence is undisturbed).
3. Mathematical Evaluation of Pause:
   $$ > \begin{aligned} > \text{Baseline Sinus Cycle Length (P-P interval)} &= R_1\text{–}R_2 = 800\text{ ms} \\ > \text{Expected Fully Compensatory Pause} &= 2 \times (P\text{–}P) = 2 \times 800\text{ ms} = 1600\text{ ms} \\ > \text{Observed Pre- and Post-Ectopic Interval} &= (R_1\text{–}R_{\text{ectopic}}) + (R_{\text{ectopic}}\text{–}R_2) \\ > &= 520\text{ ms} + 880\text{ ms} = \mathbf{1400\text{ ms}} \\ > \text{Conclusion} &: 1400\text{ ms} < 1600\text{ ms} \implies \mathbf{Non\text{-}compensatory\ pause} > \end{aligned} > $$
4. Management and Indications for Referral:
   • Management: Reassurance and discharge; no pharmacological therapy or activity restrictions required in an asymptomatic child with structurally normal heart.
   • Red-Flag Criteria Warranting Referral:
     • Ectopy increases in frequency during exercise or exertion.
     • Presence of runs of atrial tachycardia ($\ge 3$ consecutive beats) or supraventricular tachycardia (SVT).
     • Associated structural heart disease, ventricular dysfunction, or family history of inherited channelopathies/cardiomyopathies.

1. Diagnosis and ECG Criteria:
   • Diagnosis: Atrial Fibrillation (AF) with rapid ventricular response.
   • Diagnostic Criteria:
     • Irregularly irregular R-R intervals without a repetitive periodic pattern.
     • Absence of distinct, organized, uniform P waves.
     • Presence of rapid, polymorphic, low-amplitude baseline undulations (fibrillatory or "f" waves at rates of $350\text{–}600\text{ beats/min}$).
     • Narrow QRS complexes ($< 0.09\text{ s}$), unless bundle branch block or rate-dependent aberrancy is present.
2. Pediatric Etiologies / Associated Conditions:
   • Post-Fontan palliation (single ventricle pathways) or post-atrial switch repair (Senning / Mustard for D-TGA).
   • Rheumatic heart disease with severe mitral stenosis and left atrial enlargement.
   • Ebstein anomaly of the tricuspid valve (often associated with accessory pathways / WPW).
   • Hyperthyroidism / Thyrotoxicosis.
3. Emergency Electrical Cardioversion Protocol:
   • Mode: Synchronized electrical cardioversion (Sync mode must be engaged to prevent delivery on T-wave resulting in ventricular fibrillation).
   • Initial Energy Dose: $0.5\text{–}1.0\text{ J/kg}$ biphasic.
   • Subsequent Escalation: If ineffective, escalate to $2.0\text{ J/kg}$ biphasic.
4. Pharmacological Rate Control Protocol (Hemodynamically Stable):
   • First-line Agent: Esmolol (ultra-short-acting cardioselective $\beta_1$-antagonist) or Diltiazem.
   • Esmolol Regimen:
     • IV Loading dose: $500\ \mu\text{g/kg}$ ($0.5\text{ mg/kg}$) over 1 minute.
     • IV Continuous maintenance infusion: Start at $50\ \mu\text{g/kg/min}$, titrated by $50\ \mu\text{g/kg/min}$ every 5–10 minutes up to a maximum of $200\text{–}300\ \mu\text{g/kg/min}$ based on heart rate targets ($< 110\text{ bpm}$).

1. Pacing Modality and ECG Characteristics:
   • Modality: Atrial Pacing (with intact native atrioventricular conduction).
   • ECG Characteristics:
     • Sharp, narrow, vertical pacing deflection (pacemaker spike) immediately preceding each P wave.
     • P-wave morphology that differs from sinus P waves (reflecting ectopic atrial depolarization origin from epicardial wire site).
     • Stable, physiologic PR interval followed by a normal, narrow native QRS complex and normal T wave.
2. NBG Generic Pacemaker Code:
   • AAI (Paced: Atrium; Sensed: Atrium; Response: Inhibited).
3. Electrophysiological Prerequisite:
   • Intact, competent, and functioning native Atrioventricular (AV) node and His-Purkinje conduction system (absence of second-degree or complete AV nodal block).
4. Bedside Troubleshooting Protocol for Loss of Capture:
   • Step 1 (Check Hardware & Connections): Verify integrity of pacing cables, check cable polarity, ensure pins are firmly seated into the connector block, and verify that the external pacemaker battery is operational.
   • Step 2 (Increase Current Output): Gradually increase the pacing output (milliamperes, mA) to at least 2 to 3 times the capture threshold (or turn to maximum output in an emergency).
   • Step 3 (Adjust Sensitivity / Polarity): Switch from unipolar to bipolar pacing configuration (or vice versa), and check the sensing threshold to prevent under-sensing competition.
   • Step 4 (Emergency Backup Conversion): If atrial pacing fails to elicit ventricular systole due to developing AV block, immediately switch the pacemaker mode to ventricular pacing (VVI or VOO) using ventricular epicardial wires, or administer IV Isoproterenol ($0.05\text{–}0.1\ \mu\text{g/kg/min}$) while preparing transcutaneous pacing.

1. ECG Strip Analysis:
   $$ > \begin{aligned} > \text{Atrial Rate (P-P interval = 400 ms)} &= \frac{60000}{400} = \mathbf{150\ \text{beats/min}} \\ > \text{Ventricular Rate (R-R interval = 1200 ms)} &= \frac{60000}{1200} = \mathbf{50\ \text{beats/min}} \\ > \text{Conduction Ratio} &= \frac{150}{50} = \mathbf{3:1} \\ > \text{Diagnosis} &: \mathbf{\text{High-grade (3:1) Atrioventricular Block with narrow QRS escape}} > \end{aligned} > $$
2. Mobitz Type I vs. Mobitz Type II Second-Degree AV Block:
   • Anatomical Site of Block:
     • Mobitz I: AV Node (supra-Hisian, proximal to the bundle of His in $> 75\%$ of cases).
     • Mobitz II: Infranodal / Infracardiac (intra-Hisian or infra-Hisian / bundle branches).
   • Response to Exercise / Atropine:
     • Mobitz I: Improves AV nodal conduction (AV conduction ratio improves or block resolves).
     • Mobitz II: Worsens block (increases atrial rate, causing increased infra-nodal fatigue and higher block ratio).
   • Risk of Progression to Complete AV Block:
     • Mobitz I: Low risk; generally benign and rarely progresses abruptly.
     • Mobitz II: Extremely high risk; frequently and unpredictably progresses to complete heart block / ventricular asystole.
3. Prognostic Significance of Escape QRS Width:
   • Narrow QRS ($< 0.08\text{–}0.09\text{ s}$): Pacemaker site is junctional (His bundle region); intrinsically more reliable rate ($40\text{–}60\text{ bpm}$), responsive to autonomic catecholaminergic drive, and carries lower sudden death risk.
   • Wide QRS ($\ge 0.10\text{ s}$): Pacemaker site is infra-Hisian / ventricular myocardium; inherently unstable, prone to sudden asystolic arrest, slow ventricular rate ($< 40\text{ bpm}$), unresponsive to atropine, and indicates high risk for syncope/sudden cardiac death.
4. Class I Indications for Permanent Pacemaker Implantation:
   • Symptomatic advanced second-degree or third-degree (complete) AV block (syncope, presyncope, heart failure, exercise intolerance).
   • Congenital third-degree AV block with an average resting heart rate $< 50\text{–}55\text{ bpm}$ in infants or $< 40\text{–}45\text{ bpm}$ in older children.
   • Congenital third-degree AV block associated with wide QRS escape rhythm, complex ventricular ectopy, or ventricular dysfunction.
   • Postoperative advanced second- or third-degree AV block that persists $\ge 7\text{–}10\text{ days}$ following cardiac surgery.

Normal Atrial Input (P-P = 400 ms, 150 bpm)
        │
        ├── P wave 1 ──► Conducted to Ventricles (Narrow QRS)
        ├── P wave 2 ──► Blocked at AV Junction
        └── P wave 3 ──► Blocked at AV Junction
                │
                ▼
Ventricular Response = 50 bpm (3:1 Fixed Conduction)

1. Electrocardiographic Interpretation:
   • Primary finding: Broad/wide QRS complex rhythm ($\text{QRS duration} > 0.09\text{ seconds}$ for a 6-year-old child) with regular tachycardia at ~190 bpm.
   • Insufficiency of single lead: A single lead cannot assess the frontal plane QRS axis, identify atrioventricular (AV) dissociation, detect capture/fusion beats across precordial leads, or reliably differentiate ventricular tachycardia (VT) from supraventricular tachycardia (SVT) with aberrant conduction. A full 12-lead ECG is mandatory.
2. Differential Diagnosis of Pediatric Wide Complex Tachycardia:
   • Ventricular Tachycardia (VT) (monomorphic or polymorphic).
   • Supraventricular Tachycardia (SVT) with rate-dependent aberrancy (bundle branch block).
   • Pre-excited SVT / Antidromic Atrioventricular Reentrant Tachycardia (AVRT) via an accessory pathway (e.g., Wolff-Parkinson-White syndrome).
   • Toxic-metabolic disturbance (e.g., severe hyperkalemia, sodium channel blocker toxicity like tricyclic antidepressants).
3. Bedside Evaluation Checklist:
   • Step 1: Rapidly assess airway, breathing, circulation, and mental status; attach continuous cardiopulmonary monitor, non-invasive blood pressure, and pulse oximeter.
   • Step 2: Obtain an immediate, high-quality standard 12-lead ECG and a long rhythm strip (Lead II and V1).
   • Step 3: Interrogate the 12-lead ECG for signs of VT:
     • AV dissociation (P waves marching independently through QRS complexes).
     • Fusion beats (Dressler beats) or capture beats.
     • Extreme QRS axis deviation ("northwest axis" / $-90^\circ$ to $\pm 180^\circ$).
     • Concordance across precordial leads (all positive or all negative V1–V6).
     • QRS duration $>0.09\text{ s}$ (in children $<4$ years) or $>0.10\text{ s}$ (in children $>4$ years).
   • Step 4: Establish intravenous (IV) or intraosseous (IO) access and draw emergent labs: serum electrolytes ($\text{K}^+$, $\text{Ca}^{2+}$, $\text{Mg}^{2+}$), venous blood gas, and cardiac troponin.
   • Step 5: Assume ventricular tachycardia until proven otherwise; never administer verapamil in wide complex tachycardia in pediatrics.
4. Management Protocol:
   • Hemodynamically Stable:
     • If regular, monomorphic, and suspected SVT with aberrancy: Trial of rapid IV push Adenosine: Initial dose $0.1\text{ mg/kg}$ (maximum first dose $6\text{ mg}$), followed immediately by a rapid $5\text{–}10\text{ mL}$ normal saline flush. If ineffective within 1–2 minutes, administer a second dose of $0.2\text{ mg/kg}$ (maximum second dose $12\text{ mg}$).
     • If VT is confirmed or suspected: IV Amiodarone $5\text{ mg/kg}$ infused over 20–60 minutes (with continuous ECG and BP monitoring), OR IV Procainamide $15\text{ mg/kg}$ infused over 30–60 minutes.
   • Hemodynamically Unstable (Hypotension, altered sensorium, poor perfusion):
     • Immediate synchronized electrical cardioversion: Initial energy dose of $\mathbf{0.5\text{ to }1\text{ J/kg}}$.
     • If refractory to the first shock, increase the energy dose to $\mathbf{2\text{ J/kg}}$.
     • Provide procedural sedation/analgesia (e.g., IV Ketamine $1\text{ mg/kg}$ or IV Midazolam $0.1\text{ mg/kg}$) if time and clinical stability permit, but do not delay electrical therapy.

flowchart TD
    A[Wide QRS Tachycardia on Monitor] --> B{Check Hemodynamic Stability}
    B -->|Unstable: Hypotension/Poor Perfusion| C[Synchronized Cardioversion 0.5 - 1 J/kg]
    C -->|Refractory| D[Increase to 2 J/kg]
    B -->|Stable: Alert/Normal Perfusion| E[Obtain Immediate 12-Lead ECG]
    E --> F{Morphology / Signs of VT?}
    F -->|AV Dissociation / Fusion Beats / VT| G[IV Amiodarone 5 mg/kg or Procainamide 15 mg/kg]
    F -->|Suspected SVT with Aberrancy| H[Trial IV Adenosine 0.1 mg/kg rapid push]

1. Definitive Intervention:
   • Immediate Synchronized Electrical Cardioversion.
2. Procedural Checklist for Synchronized Cardioversion:
   • Step 1: Ensure high-flow oxygen delivery and bag-valve-mask ventilatory support if required.
   • Step 2: Power on the manual biphasic defibrillator and apply appropriate pediatric self-adhesive multifunction pads (anteroposterior placement or right infraclavicular/left axillary).
   • Step 3: Activate the "SYNC" button on the defibrillator; confirm that synchronization markers (dots or arrows) appear consistently on every peak of the QRS complex (R wave).
   • Step 4: Select the appropriate energy level based on patient weight ($0.5\text{ to }1\text{ J/kg}$).
   • Step 5: Charge the machine; perform a visual and verbal safety check: announce "Stand clear!", ensure oxygen source is moved $\ge 1\text{ meter}$ away.
   • Step 6: Depress and HOLD the shock button until the energy discharges (holding is essential because delivery is delayed until the next sensed R wave).
   • Step 7: Immediately reassess rhythm on the monitor and re-evaluate central femoral pulse and hemodynamic status.
3. Energy Dose Calculations:
   $$ > \begin{aligned} > \text{Initial Energy Dose (0.5 – 1 J/kg)} &= 0.5\text{ to }1.0\text{ J/kg} \times 16\text{ kg} \\ > &= \mathbf{8\text{ to }16\text{ Joules}} \\ > \text{Subsequent Energy Dose (2 J/kg)} &= 2.0\text{ J/kg} \times 16\text{ kg} \\ > &= \mathbf{32\text{ Joules}} > \end{aligned} > $$
4. Resuscitation Protocol for Pulseless VT (Cardiac Arrest):
   • Step 1: Immediately start high-quality CPR (compression rate 100–120/min, depth $\ge 1/3$ AP chest diameter or $\approx 5\text{ cm}$, ratio 15:2 with 2 rescuers).
   • Step 2: Disengage the "SYNC" mode to switch the machine to Unsynchronized Defibrillation.
   • Step 3: Deliver an unsynchronized shock at $2\text{ J/kg}$ ($32\text{ J}$ for $16\text{ kg}$), immediately resume CPR for 2 minutes without pause for pulse check.
   • Step 4: Prepare subsequent shocks at $4\text{ J/kg}$ ($64\text{ J}$) for persistent pulseless VT, alongside IV/IO Epinephrine $0.01\text{ mg/kg}$ ($0.1\text{ mL/kg}$ of $1:10,000$ solution) every 3–5 minutes and Amiodarone $5\text{ mg/kg}$ bolus after the third shock.

1. Heart Rate Calculation:
   $$ > \begin{aligned} > \text{Method 1 (Large Square Method)} &= \frac{300}{\text{Number of large squares between consecutive R waves}} \\ > &= \frac{300}{5} = \mathbf{60\text{ beats/min}} \\ > \text{Method 2 (Small Square Method)} &= \frac{1500}{\text{Number of small squares between consecutive R waves}} \\ > &= \frac{1500}{25} = \mathbf{60\text{ beats/min}} > \end{aligned} > $$
2. Rhythm Classification:
   • Normal resting heart rate range for a 10-year-old child: $60\text{ to }100\text{ beats/min}$ (resting awake; can drop to $45\text{–}50\text{ bpm}$ during deep sleep).
   • Classification: Borderline Normal Resting Heart Rate / Mild Sinus Bradycardia (if resting awake and below normal percentiles for baseline).
3. Etiologies of Bradycardia in Children:
   • Physiological:
     • High athletic conditioning / aerobic training (increased vagal tone).
     • Sleep / deep nocturnal rest.
     • Vagal stimulation (coughing, straining, breath-holding, ocular pressure).
     • Familial/genetic constitutionally low resting sinus rate.
   • Pathological:
     • Hypothermia.
     • Hypothyroidism.
     • Increased intracranial pressure (Cushing's triad: bradycardia, hypertension, irregular breathing).
     • Sick Sinus Syndrome (Sinus node dysfunction) or postoperative sinus node trauma (e.g., post-Fontan, Mustard/Senning).
     • Drugs (beta-blockers, calcium channel blockers, digoxin, clonidine).
     • Severe hypoxia or acidosis (late decompensation in children).
4. Indications for Further Workup (Holter / Echocardiography):
   • Inability to accelerate heart rate appropriately with exercise or active crying (chronotropic incompetence).
   • History of exertional syncope, presyncope, dizziness, or easy fatigability.
   • Coexisting structural congenital heart disease or prior cardiac surgery.
   • Prolonged sinus pauses ($>3\text{ seconds}$) or significant junctional/ventricular escape rhythms on resting ECG.
   • Presence of second- or third-degree atrioventricular (AV) block.

1. Identification and Diagnostic Features:
   • Phenomenon: Muscle Tremor / Somatic Movement Artifact.
   • Key Electrocardiographic Features:
     • Visible underlying normal, narrow QRS complexes and T waves "marching through" the chaotic deflections at regular intervals (constant R-R interval).
     • Complete discordance between the chaotic rhythm (which mimics life-threatening ventricular fibrillation) and the clinical picture of a hemodynamically stable, crying infant with palpable pulses.
     • Complete absence of stereotypic QRS morphology or electrical axis consistency across all leads.
2. Pediatric Triggers:
   • Shivering secondary to cold exposure/hypothermia.
   • Active infant crying, struggling, or gross somatic movement.
   • Poor skin-electrode contact (e.g., dry conducting gel, oily skin, vernix/cream residue).
   • Neurological tremors, jitteriness, or seizure activity.
3. Bedside Troubleshooting Checklist:
   • Step 1: Warm the environment; provide warm blankets and eliminate infant shivering.
   • Step 2: Calm and pacify the infant (pacifier, non-nutritive sucking, 24% oral sucrose, maternal holding or soothing feed).
   • Step 3: Inspect all electrodes; replace dry or detached pads with fresh pediatric-sized disposable pre-gelled Ag/AgCl electrodes.
   • Step 4: Ensure skin preparation: clean with alcohol or mild soap and water, and thoroughly dry the skin before electrode application to reduce skin-electrode impedance.
   • Step 5: Relocate limb lead electrodes from distal extremities (wrists/ankles) to proximal bony areas or the torso (modified Mason-Likar configuration) to reduce skeletal muscle interference.
   • Step 6: Verify firm cable connections; activate the machine's low-pass muscle tremor filter (usually $35\text{–}40\text{ Hz}$).
4. Other Common Technical Artifacts:
   • Powerline / Alternating Current (60 Hz or 50 Hz) Interference: Perfectly uniform, continuous, high-frequency baseline oscillations caused by improper electrical grounding of the machine or nearby electrical equipment (e.g., radiant warmers, infusion pumps).
   • Wandering Baseline Artifact: Slow, undulating baseline shifts typically caused by infant respiration, deep chest wall excursion, or loose electrodes swinging with movement.

1. Normality and Physiological Basis:
   • Normal Pediatric ECG (Juvenile Precordial Pattern).
   • Physiological basis: In children between 7 days of age and ~8–12 years, the T wave in lead V1 is normally inverted, while the T wave in lead V6 is upright. The $rSR'$ pattern in V1 with normal QRS duration ($<0.08\text{ s}$) represents physiological terminal conduction delay through the crista supraventricularis of the right ventricular outflow tract.
2. Chronological Evolution of T-Wave in Lead V1:
   • Day 0 to Day 3 of life: Normally upright (reflects the high in utero right ventricular pressures).
   • Day 3 to Day 7 of life: Flips and becomes inverted.
   • Day 7 to approximately 8–12 years of age: Must remain inverted (the normal juvenile pattern).
   • Late childhood / Adolescence ($\ge 10\text{–}14$ years): Flips back and becomes permanently upright (adult pattern).
   • Clinical pearl: An upright T wave in V1 between 7 days and 8 years is always abnormal and strongly indicates right ventricular hypertrophy.
3. Distinguishing Juvenile Pattern from Pathological RVH:
   • T-wave polarity in V1: Juvenile pattern has an inverted T wave; RVH with strain has an abnormally upright T wave in V1 (after day 7 of life until ~8 years).
   • R-wave amplitude in V1: Juvenile pattern shows $R$ wave within the normal range for age ($<98\text{th}$ percentile); RVH shows tall $R$ wave $>98\text{th}$ percentile or a pure $R$ wave without an $S$ wave.
   • Frontal plane QRS axis: Juvenile pattern displays an axis normal for age ($0^\circ\text{ to }+90^\circ$); RVH shows pathological right axis deviation ($>+100^\circ\text{ to }+120^\circ$).
4. Normal RV Dominance in a 3-Day-Old Neonate:
   • Marked Right Axis Deviation (mean QRS axis $+90^\circ\text{ to }+180^\circ$, commonly around $+110^\circ\text{ to }+130^\circ$).
   • Tall R

1. Electrocardiographic Correlations:
   • a. Ventricular depolarization: QRS complex
   • b. Ventricular repolarization: T wave
   • c. Onset of atrial depolarization to onset of ventricular depolarization: PR interval
   • d. Isoelectric period between ventricular depolarization and repolarization: ST segment
   • e. Total duration of ventricular electrical systole: QT interval
2. PR Interval Electrophysiology and Reference Limits:
   • Definition: Represents the total time taken for atrial depolarization, conduction through the atrioventricular (AV) node, the bundle of His, and the Purkinje network until ventricular myocardial depolarization begins.
   • Infant (<1 year): Upper limit of normal is approximately 0.14 seconds (140 ms).
   • Adolescent (>12 years): Upper limit of normal is approximately 0.18 to 0.20 seconds (180–200 ms).
3. Grid Paper Calibration Calculations:
   $$ > \begin{aligned} > \text{Paper speed} &= 25\text{ mm/s} \implies 1\text{ mm} = \frac{1000\text{ ms}}{25} = \mathbf{40\text{ ms (0.04 s)}} \\ > \text{One large box (horizontal, 5 mm)} &= 5 \times 40\text{ ms} = \mathbf{200\text{ ms (0.20 s)}} \\ > \text{Voltage calibration} &= 10\text{ mm/mV} \implies 1\text{ mm (vertical)} = \mathbf{0.1\text{ mV}} \\ > \text{Two large boxes (vertical, 10 mm)} &= 10 \times 0.1\text{ mV} = \mathbf{1.0\text{ mV}} > \end{aligned} > $$
4. Ventricular Action Potential Ion Currents:
   • Phase 0 (Rapid depolarization): Inward sodium current ($I_{\text{Na}}$) through voltage-gated fast $Na^+$ channels.
   • Phase 2 (Plateau): Balance between inward calcium current ($I_{\text{Ca,L}}$) via L-type calcium channels and outward delayed rectifier potassium currents ($I_{\text{Kr}}, I_{\text{Ks}}$).
   • Phase 3 (Rapid repolarization): Predominant outward delayed rectifier potassium currents ($I_{\text{Kr}}, I_{\text{Ks}}$) with closure of L-type calcium channels.

graph LR
    A[Sinoatrial Node Discharge] --> B[P Wave: Atrial Depolarization]
    B --> C[PR Segment: AV Nodal Delay]
    C --> D[QRS Complex: Ventricular Depolarization]
    D --> E[ST Segment: Plateau Phase 2]
    E --> F[T Wave: Ventricular Repolarization Phase 3]

Note on the U wave: A small deflection following the T wave, representing delayed repolarization of mid-myocardial M-cells or Purkinje fibers. It becomes prominent in hypokalemia and bradycardia.

1. Sequential ECG Changes in Hyperkalemia:
   • Early (Serum $K^+ \approx 5.5\text{--}6.5\text{ mEq/L}$): Tall, peaked, symmetrical, narrow-based "tented" T waves (most prominent in precordial leads V2–V4).
   • Moderate (Serum $K^+ \approx 6.5\text{--}7.5\text{ mEq/L}$): Prolongation of PR interval, progressive flattening and eventual loss/disappearance of P waves.
   • Severe (Serum $K^+ \approx 7.5\text{--}8.5\text{ mEq/L}$): Widening and slurring of the QRS complex, ST-segment depression or elevation mimicking injury patterns.
   • Terminal / Critical (Serum $K^+ > 8.5\text{ mEq/L}$): Merging of widened QRS with the T wave forming a classical biphasic "sine wave" rhythm, leading to ventricular fibrillation or asystole.
2. Three-Step Immediate Pharmacological Management:
   • Step 1: Membrane Stabilization: IV Calcium Gluconate 10% (first-line) to prevent lethal dysrhythmias.
   • Step 2: Intracellular Shift of Potassium:
     • IV Regular Insulin (0.1 unit/kg) combined with 25% Dextrose (2 mL/kg) or 10% Dextrose (5 mL/kg) infused over 30 minutes.
     • Nebulized Salbutamol (albuterol): 2.5 to 5 mg nebulized over 10–15 minutes (stimulates $\beta_2$-mediated $Na^+/K^+$ ATPase).
     • IV Sodium Bicarbonate: 1–2 mEq/kg over 10–15 minutes (if metabolic acidosis is present).
   • Step 3: Potassium Removal / Elimination:
     • IV Furosemide: 1–2 mg/kg IV (if renal perfusion permits).
     • Potassium-binding resins: Sodium or calcium polystyrene sulfonate (1 g/kg orally or per rectum) or sodium zirconium cyclosilicate (SZC).
     • Emergency Renal Replacement Therapy (Hemodialysis / Hemofiltration / Peritoneal Dialysis) if refractory or in established anuric renal failure.
3. Calcium Gluconate Dose and Administration:
   $$ > \begin{aligned} > \text{Recommended Dose} &= 0.5\text{ mL/kg of 10\% Calcium Gluconate} \quad (\approx 50\text{ mg/kg}) \\ > \text{Volume for 16 kg Child} &= 16\text{ kg} \times 0.5\text{ mL/kg} = \mathbf{8.0\text{ mL of 10\% Calcium Gluconate}} > \end{aligned} > $$
   • Route: Slow intravenous push via central or secure peripheral line.
   • Rate: Infuse over 3 to 5 minutes under continuous ECG monitoring.
   • Onset of action: 1 to 3 minutes.
   • Duration of action: 30 to 60 minutes (can repeat dose once after 5–10 minutes if ECG changes persist).
4. Mechanism of Myocardial Stabilization by Calcium:
   • Elevated extracellular potassium causes partial depolarization of the resting membrane potential (making it less negative, closer to zero), which inactivates voltage-gated fast sodium channels, reducing myocardial excitability and conduction velocity.
   • Hypercalcemia increases extracellular calcium, which shields membrane surface charges and shifts the threshold potential to a less negative (higher) voltage.
   • This restores the normal gradient between the resting membrane potential and threshold potential, restoring fast sodium channel availability and normal action potential conduction velocity without altering circulating potassium levels.

1. Primary Electrocardiographic Diagnosis:
   • Diagnosis: Low Atrial Rhythm (or Inferior / Caudal Ectopic Atrial Rhythm).
   • Diagnostic ECG features:
     • Inverted (negative) P waves in inferior leads (II, III, and aVF).
     • Upright (positive) P wave in lead aVR.
     • Normal or mildly shortened PR interval (usually $\ge 0.10$ seconds, differentiating it from junctional rhythm).
     • Narrow QRS complexes with normal ventricular conduction.
     • Normal, age-appropriate resting heart rate.
2. P-Wave Axis and Morphology Comparison:
   • Normal Sinus Rhythm:
     • Pacemaker site: High right atrium near the superior vena cava.
     • P-wave axis: Inferior and leftward ($+15^\circ$ to $+75^\circ$).
     • Leads II, III, aVF: Positive (upright).
     • Lead aVR: Negative (inverted).
   • Low Atrial Rhythm:
     • Pacemaker site: Lower right or left atrium near the coronary sinus or inferior vena cava.
     • Depolarization wave spreads retrograde (caudo-cranial direction, bottom-to-top).
     • P-wave axis: Superiorly oriented ($-60^\circ$ to $-120^\circ$).
     • Leads II, III, aVF: Negative (inverted).
     • Lead aVR: Positive (upright).
3. Associated Conditions in Pediatrics:
   • Increased Vagal Tone: Common in healthy adolescents, well-conditioned athletes, or during sleep/deep resting states.
   • Transient Sinus Node Suppression: Following vagal maneuvers, suctioning, or hypothermia.
   • Post-Cardiac Surgery: Sequela of surgical manipulation or cannulation near the sinus node or superior caval junction (e.g., Glenn shunt, Fontan procedure, atrial septal defect repair).
   • Pharmacological: Digoxin toxicity, $\beta$-blockers, calcium channel blockers, or dexmedetomidine.
4. Management and Clearance:
   • Intervention: No pharmacological or electrical treatment is required; this is a benign physiological variant in an asymptomatic child with a normal heart rate.
   • Pre-operative Clearance: Cleared for elective surgery under general anesthesia without additional invasive cardiac workup.
   • Sports Clearance: Fully cleared for all levels of sports participation (Class 1A–3C) without restriction.
   • Indication for further evaluation: Indicated only if accompanied by syncope, presyncope, pathological bradycardia (<40 bpm), or daytime pauses $>3$ seconds on 24-hour Holter monitoring.

1. True / False Responses:
   • a. True (T): Full-term neonates exhibit physiological right ventricular dominance due to high fetal pulmonary vascular resistance, resulting in a rightward axis ($+90^\circ$ to $+180^\circ$).
   • b. True (T): Transplacental passage of maternal IgG antibodies against Ro/SSA and La/SSB causes autoimmune myocarditis and permanent fibrosis of the fetal AV conduction tissue.
   • c. False (F): An $rSr'$ pattern in V1 with normal QRS duration is a frequent normal physiological variant in healthy children, reflecting delayed depolarization of the crista supraventricularis.
   • d. True (T): PR interval increases with age (infants: 80–140 ms; children: 100–160 ms; adolescents: 120–200 ms) due to increasing atrial size and decreased resting heart rates.
   • e. False (F): In lead V1, T waves are upright at birth, invert by day 3 to 7 of life, and must remain inverted throughout childhood until approximately 8 to 12 years of age; an upright T wave in V1 between 1 week and 8 years is abnormal and indicates right ventricular hypertrophy.
2. Physiological Basis of RV Dominance in Neonates:
   • In fetal life, the lungs are fluid-filled with high pulmonary vascular resistance (PVR).
   • The fetal right ventricle works against systemic afterload, pumping approximately 55–60% of total combined cardiac output across the ductus arteriosus into the descending aorta.
   • This high pressure work leads to physiological right ventricular wall thickness that equals or exceeds left ventricular wall thickness at term birth.
3. Normal Frontal QRS Axis Ranges:
   • Day 1 Newborn: $+90^\circ \text{ to } +180^\circ$ (mean $\approx +135^\circ$).
   • Adolescent (16 years): $0^\circ \text{ to } +90^\circ$ (mean $\approx +50^\circ \text{ to } +65^\circ$).
4. Corrected QT (QTc) Upper Limits (Bazett's Formula):
   • Infants younger than 6 months: $\le 0.45\text{ to } 0.46\text{ seconds (450–460 ms)}$ (values $>460\text{ ms}$ are borderline; $>470\text{ ms}$ prolonged).
   • Children and Adolescents (>1 year):
     • Males: $\le 0.44\text{ seconds (440 ms)}$ (borderline 440–460 ms; prolonged $>460\text{ ms}$).
     • Females: $\le 0.45\text{ seconds (450 ms)}$ (borderline 450–470 ms; prolonged $>470\text{ ms}$).

1. Electrocardiographic Diagnosis and Criteria:
   • Diagnosis: Respiratory Sinus Arrhythmia (normal sinus arrhythmia).
   • Diagnostic Criteria:
     • Normal sinus P-wave morphology (positive in leads I, II, and aVF; negative in aVR) with a constant PR interval.
     • Phasic variation of the P-P (and R-R) intervals exceeding 10% (or $>120\text{ ms}$ / 3 small boxes between shortest and longest cycle length) that corresponds with the respiratory cycle.
2. Physiological Autonomic Mechanism:
   • Inspiration:
     • Negative intrathoracic pressure increases venous return to the right atrium, transiently stretching right atrial stretch receptors (Bainbridge reflex) and triggering pulmonary stretch receptor discharge (Hering-Breuer reflex).
     • Medullary vagal center activity is centrally inhibited, leading to decreased parasympathetic (vagal) outflow to the sinoatrial (SA) node, causing an increase in heart rate.
   • Expiration:
     • Intrathoracic pressure rises, reducing venous return and thoracic vascular stretch.
     • Medullary cardiac vagal efferents are reactivated, increasing acetylcholine release at SA nodal muscarinic ($M_2$) receptors, resulting in increased parasympathetic tone and slowing of the heart rate.
3. Mathematical Calculation of Heart Rate Variation:
   $$ > \begin{aligned} > \text{HR}_{\text{inspiration (maximum)}} &= \frac{60}{\text{Minimum R-R}} = \frac{60}{0.64\text{ s}} = \mathbf{93.75\text{ bpm}} \approx \mathbf{94\text{ bpm}} \\ > \text{HR}_{\text{expiration (minimum)}} &= \frac{60}{\text{Maximum R-R}} = \frac{60}{0.92\text{ s}} = \mathbf{65.22\text{ bpm}} \approx \mathbf{65\text{ bpm}} \\ > \Delta \text{HR} &= 93.75 - 65.22 = \mathbf{28.5\text{ bpm}} > \end{aligned} > $$
4. Management and Counseling:
   • Reassurance: Counsel parents that respiratory sinus arrhythmia is a completely benign, healthy physiological manifestation of robust cardiac autonomic vagal tone in young children.
   • Investigations: No echocardiography, 24-hour Holter monitoring, or pharmacotherapy is required.
   • Sports Clearance: Full, unrestricted clearance for all competitive sports and athletic training.
   • Confirmatory Bedside Test: Disappears completely with breath-holding, exercise, or atropine administration (confirming intact autonomic responsiveness).

1. Electrocardiographic Diagnosis & Criteria:
   • Diagnosis: Sinus bradycardia.
   • Criteria:
     • Heart rate below the lower limit of normal for age (<60 beats/min in school-aged children).
     • Normal P wave axis (upright in leads I, II, and aVF; inverted in aVR).
     • Consistent 1:1 atrioventricular (AV) conduction with a constant, normal PR interval preceding every QRS complex.
     • Normal QRS morphology and duration.
2. Secondary Non-Cardiac Etiologies:
   • Hypothyroidism (severe or juvenile myxedema).
   • Increased intracranial pressure (Cushing triad: bradycardia, hypertension, irregular respirations).
   • Accidental or therapeutic hypothermia (core temperature <35°C).
   • Severe electrolyte derangements (hyperkalemia, severe hypermagnesemia).
   • Pharmacological toxicity (beta-blockers, calcium channel blockers, digoxin, clonidine).
3. Diagnostic Workup:
   • Serum thyroid-stimulating hormone (TSH) and free thyroxine (Free T4) levels.
   • Serum anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies (to confirm autoimmune Hashimoto thyroiditis).
   • Serum electrolytes ($Na^+$, $K^+$, $Ca^{2+}$, $Mg^{2+}$) and renal function tests.
   • 24-hour ambulatory Holter monitoring to evaluate intrinsic sinoatrial node dysfunction if rhythm persists after metabolic correction.
4. Acute Pharmacological Management for Hemodynamic Instability:
   • First-line Agent (if vagally mediated or AV block suspected):
     • Atropine sulfate:
       $$ > \begin{aligned} > \text{Dose} &= \mathbf{0.02\text{ mg/kg IV/IO}} \\ > \text{Minimum single dose} &= 0.1\text{ mg (to avoid paradoxical bradycardia)} \\ > \text{Maximum single dose} &= 0.5\text{ mg in children (1.0 mg in adolescents)} > \end{aligned} > $$
       • May repeat once after 3–5 minutes (maximum cumulative dose: 1.0 mg for children, 2.0 mg for adolescents).
   • Alternative/Second-line Agent (Catecholaminergic support):
     • Epinephrine IV/IO infusion: $0.05 \text{ to } 0.1 \text{ mcg/kg/min}$, titrated to age-appropriate target heart rate and perfusion.

graph TD
    A[Symptomatic Pediatric Bradycardia] --> B{Compromised Perfusion? <br/>Hypotension, AMS, Shock}
    B -->|No| C[Investigate & Treat Secondary Causes <br/>TSH, ICP, Core Temp, Toxins]
    B -->|Yes| D[Support ABCs + High-flow O2]
    D --> E{HR < 60 bpm despite <br/>adequate oxygenation/ventilation?}
    E -->|Yes| F[Start CPR]
    F --> G{Suspected increased vagal tone <br/>or primary AV block?}
    G -->|Yes| H[Atropine 0.02 mg/kg IV/IO <br/>Min: 0.1 mg, Max: 0.5 mg]
    G -->|No| I[Epinephrine 0.01 mg/kg IV/IO <br/>1:10,000 every 3-5 mins]
    I --> J[Consider Infusion: 0.05-1 mcg/kg/min]

1. Electrocardiographic Diagnosis & Distinguishing Features:
   • Diagnosis: Sinus tachycardia.
   • Distinguishing Features from SVT:
     • P wave morphology: Identifiable, upright P waves in leads I, II, and aVF with a normal frontal plane P-wave axis ($0^\circ \text{ to } +90^\circ$).
     • Rate variability: Beat-to-beat variability present on telemetry or during respiration/activity changes (in SVT, the rate is fixed and invariable).
     • Gradual rate change: Onset and termination occur gradually (warm-up and cool-down phenomena), whereas SVT starts and terminates abruptly.
     • Absolute ventricular rate: Usually <180 beats/min in children >1 year (<220 beats/min in infants), whereas SVT typically exceeds these thresholds.
2. Physiological Heart Rate Limit & Variability:
   $$ > \begin{aligned} > \text{Maximum Anticipated HR} &= 220 - \text{Age (years)} \\ > &= 220 - 3 \\ > &= \mathbf{217\text{ beats/min}} > \end{aligned} > $$
   • Primary determinant of variability is autonomic tone balance (sympathetic acceleration versus parasympathetic withdrawal) in response to physiological stress.
3. Systemic Non-Cardiac Etiologies:
   • Dehydration, hypovolemia, or septic shock.
   • Severe anemia (compensatory hyperdynamic circulation).
   • Hyperthyroidism / thyrotoxic crisis.
   • Febrile illness (increases heart rate by approximately 10 beats/min per 1°C elevation).
   • Toxic ingestions or sympathomimetic exposure (salbutamol, caffeine, theophylline, decongestants).
4. Management Strategy:
   • Direct antiarrhythmic agents are strictly contraindicated, as sinus tachycardia is a compensatory physiological response.
   • Targeted Etiological Management:
     • Restore intravascular volume: $20\text{ mL/kg}$ normal saline ($0.9\% \text{ NaCl}$) bolus IV over 20–30 minutes for dehydration.
     • Antipyresis: Paracetamol $15\text{ mg/kg}$ orally or rectally every 4–6 hours (maximum $60\text{ mg/kg/day}$).
     • Screen for and treat underlying infection: Blood cultures, urine analysis, and empirical parenteral antibiotics if sepsis is suspected.
     • Correct severe anemia with packed red blood cell transfusion ($10\text{ mL/kg}$) if indicated.

1. ECG Abnormality & Threshold:
   • Abnormality: ST-segment depression (horizontal or downsloping) or widespread reciprocal ST-segment changes.
   • Quantitative Threshold:
     • Depression of the ST segment $\ge 0.1\text{ mV}$ ($1\text{ mm}$) measured $60 \text{ to } 80\text{ ms}$ after the J-point in two or more anatomically contiguous leads.
2. Morphological Classification:
   • Three Types:
     • Horizontal ST-segment depression.
     • Downsloping ST-segment depression.
     • Upsloping ST-segment depression (slow upsloping).
   • Highest Specificity: Horizontal and downsloping ST depressions have the highest predictive value for true subendocardial myocardial ischemia.
3. Pediatric Clinical Conditions:
   • Acute myopericarditis.
   • Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA / Bland-White-Garland syndrome).
   • Kawasaki disease with coronary artery aneurysm thrombosis or stenosis.
   • Severe left ventricular outflow tract obstruction (severe aortic stenosis) with left ventricular strain.
   • Digitalis toxicity (classical scooped / "reverse tick" ST depression).
   • Severe hypokalemia (associated with prominent U waves).
4. Definitive Investigations & Initial Stabilization:
   • Biochemical Marker: Cardiac troponin I or high-sensitivity cardiac troponin T (hs-cTnT) to confirm acute cardiomyocyte necrosis.
   • Imaging: Transthoracic 2D-echocardiography to assess left ventricular regional wall motion, ejection fraction, pericardial effusion, and coronary artery origins/dimensions (Z-scores).
   • Initial Stabilization:
     • Strict bed rest and continuous cardiac telemetry.
     • Supplemental oxygen via face mask to maintain $SpO_2 > 94\%$.
     • Anti-inflammatory therapy for acute myopericarditis: Ibuprofen $10\text{ mg/kg}$ PO every 8 hours (with gastric protection) and Colchicine ($0.5\text{ mg}$ once daily if body weight $\ge 50\text{ kg}$; $0.5\text{ mg}$ every other day if $<50\text{ kg}$).

1. Diagnosis & Distinguishing Electrocardiographic Features:
   • Diagnosis: Supraventricular tachycardia (SVT) / Atrioventricular re-entrant tachycardia (AVRT).
   • Distinguishing Features:
     • Ventricular Rate: $\ge 220\text{ beats/min}$ in infants ($>180\text{ beats/min}$ in children); rate here is $280\text{ beats/min}$.
     • P wave characteristics: P waves are absent, abnormal, or retrograde (inverted in inferior leads II, III, aVF) buried within or immediately following the QRS complex.
     • R-R interval variability: Absolutely regular, fixed R-R interval with no beat-to-beat variability.
     • QRS duration: Narrow QRS complexes ($<80\text{ ms}$ in infants) without preceding normal PR intervals.
2. Vagal Maneuvers:
   • Procedure of Choice: Application of an ice bag (or cold water-filled glove) over the forehead and mid-face for 15–20 seconds, ensuring no obstruction of the infant's airway (diving reflex).
   • Contraindicated Technique: Eyeball / ocular pressure is strictly contraindicated due to risk of retinal detachment and globe injury. Carotid sinus massage is also ineffective and avoided in infants.
3. First-Line Pharmacological Agent (Adenosine):
   • Drug & Class: Adenosine (Endogenous purinergic antiarrhythmic nucleoside).
   • Mechanism of Action: Activates cardiac $A_1$ adenosine receptors, enhancing inward potassium current ($I_{K.Ado}$), causing hyperpolarization and profound transient slowing/block of AV nodal conduction.
   • Dosing Schedule:
     $$ > \begin{aligned} > \text{Initial Dose} &= \mathbf{0.1\text{ mg/kg IV/IO rapid push}} \quad (\text{Maximum: } 6\text{ mg}) \\ > \text{Second Dose (if unsuccessful)} &= \mathbf{0.2\text{ mg/kg IV/IO rapid push}} \quad (\text{Maximum: } 12\text{ mg}) > \end{aligned} > $$
   • Administration Technique:
     • Administer as an ultra-rapid IV bolus (<2 seconds) through the most proximal venous access site (preferably antecubital vein or central line).
     • Use a two-syringe technique with a 3-way stopcock, followed immediately by a rapid flush of $5 \text{ to } 10\text{ mL}$ normal saline ($0.9\% \text{ NaCl}$) to clear the drug past its short half-life (<10 seconds).
     • Continuous multi-lead ECG rhythm recording during administration.
4. Management for Hemodynamic Decompensation / Shock:
   • Synchronized Electrical Cardioversion:
     • Initial energy dose: $0.5 \text{ to } 1\text{ J/kg}$.
     • Subsequent energy dose (if refractory): Escalate to $2\text{ J/kg}$.
     • Ensure synchronizer switch is activated (flagging the R wave). Provide immediate sedation and analgesia (e.g., ketamine $1\text{ mg/kg}$ IV or midazolam $0.1\text{ mg/kg}$ IV) if time and clinical stability permit.

graph TD
    A[Infantile SVT: HR >= 220 bpm] --> B{Hemodynamically Stable?}
    B -->|Yes| C[Apply Ice to Mid-Face for 15-20 sec]
    C --> D{Restored to Sinus?}
    D -->|Yes| E[12-lead ECG: Check for Pre-excitation / Delta wave]
    D -->|No| F[Establish IV/IO Access Proximal to Heart]
    F --> G[Adenosine 0.1 mg/kg rapid push + 5-10 mL Saline flush]
    G --> H{Restored to Sinus?}
    H -->|No| I[Adenosine 0.2 mg/kg rapid push + Flush]
    H -->|Yes| E
    I -->|Fails| J[Amiodarone 5 mg/kg over 20-60 min OR Procainamide]
    B -->|No: Hypotension, Shock| K[Synchronized Cardioversion 0.5 - 1.0 J/kg]
    K --> L{Restored to Sinus?}
    L -->|No| M[Increase Energy to 2.0 J/kg Synchronized]

1. ECG Abnormality & Configuration Criteria:
   • Primary Abnormality: Premature Ventricular Complexes (PVCs / Ventricular Ectopic Beats).
   • Electrocardiographic Features: Early, wide QRS complex (>100 ms in an adolescent) not preceded by an atrial P wave, with discordant ST-T segment changes and a full compensatory pause.
   • Monomorphic vs. Polymorphic:
     • Monomorphic: Identical QRS morphology and axis across all premature beats, indicating a single ectopic arrhythmogenic focus (most commonly right ventricular outflow tract [RVOT]).
     • Polymorphic: Differing QRS morphologies and varying electrical axes, indicating multiple arrhythmogenic foci, which carries higher risk for progression to ventricular fibrillation.
2. Four-Step Diagnostic Evaluation:
   • Ambulatory ECG Monitoring: 24- to 48-hour Holter monitoring (or external patch recorder) to quantify the total PVC burden (expressed as a percentage of total beats; $>10-15\%$ confers risk of tachycardia-induced cardiomyopathy) and assess for couplets, triplets, or non-sustained ventricular tachycardia (NSVT).
   • Transthoracic Echocardiography (TTE): To rule out structural heart anomalies, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy (ARVC), and assess left ventricular dimensions and ejection fraction.
   • Exercise Stress Treadmill Test (TMT): To determine if ectopy suppresses with exercise (indicative of benign outflow tract ectopy) versus ectopy that worsens or degenerates into complex rhythms during exercise (suggestive of catecholaminergic polymorphic ventricular tachycardia [CPVT] or ischemia).
   • Biochemical & Endocrine Screening: Serum electrolytes (potassium, ionized calcium, magnesium), hemoglobin, and complete thyroid profile (TSH, Free T4).
3. First-Line Pharmacological Prescription:
   • Drug Class: Non-selective or cardioselective Beta-adrenergic blocker.
   • Drug Selection & Dosing (Oral Propranolol):
     • Medication: Tab. Propranolol hydrochloride.
     • Dose: $1 \text{ to } 2\text{ mg/kg/day}$ divided every 8 hours orally (starting dose: $0.5 \text{ to } 1\text{ mg/kg/day}$, titrate upward as needed; adult target $20 \text{ to } 40\text{ mg}$ TID).
     • Alternative: Tab. Atenolol $0.5 \text{ to } 1\text{ mg/kg}$ orally once daily (maximum: $50\text{ mg/day}$).
     • Monitoring Parameters: Resting heart rate and blood pressure prior to dose titration; screen for bronchospasm/asthma exacerbation, fatigue, and depression.
4. High-Risk "Red Flag" Indications for Urgent Admission / EP Referral:
   • History of exertional syncope or presyncope accompanying palpitations.
   • Family history of premature sudden unexplained cardiac death (SCD <40 years), unexplained drowning, or confirmed hereditary channelopathy (Long QT, Brugada, CPVT).
   • Documentation of complex ventricular ectopy: Couplets, triplets, multiform PVCs, or runs of non-sustained or sustained ventricular tachycardia.
   • Resting ECG anomalies: Corrected QT ($QTc > 460\text{ ms}$ in females), resting pre-excitation (Wolff-Parkinson-White delta waves), or epsilon waves / T-wave inversions in $V_1-V_3$ (ARVC).

1. Rhythm Identification and Distinguishing Features:
   • Diagnosis: Supraventricular Tachycardia (SVT).
   • Distinguishing features versus sinus tachycardia:
     • Heart rate: Typically >220–230 beats/min in infants (sinus tachycardia is usually <220 beats/min and fluctuates with fever, pain, or hydration).
     • P-wave morphology: P-waves are absent, obscured within the T wave, or inverted (retrograde) in inferior leads (II, III, aVF).
     • R-R interval variability: Strictly regular with zero beat-to-beat variability (sinus tachycardia exhibits respiratory sinus variation).
     • QRS duration: Narrow complex (<0.08–0.09 seconds) unless bundle branch block or rate-dependent aberrancy is present.
2. Electrophysiological Mechanism and Substrate:
   • Primary mechanism: Reentry circuit (responsible for >90% of pediatric SVT).
   • Substrate: Atrioventricular Reentrant Tachycardia (AVRT) mediated by an accessory pathway (e.g., Wolff-Parkinson-White syndrome), followed by Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
3. Acute Resuscitation Algorithm:
   • Vagal Maneuvers (first-line if hemodynamically compensated):
     • Application of an ice-water bag (slurry) to the upper half of the face covering the forehead and bridge of the nose for 10–15 seconds to trigger the diving reflex.
     • Contraindication: Ocular pressure and carotid sinus massage are strictly contraindicated in infants due to risks of retinal detachment and neurovascular compromise.
   • Pharmacological Therapy (if vagal maneuvers fail or vascular access is immediately available):
     • Intravenous / Intraosseous Adenosine: Initial dose of 0.1 mg/kg (maximum initial dose 6 mg) given as a rapid bolus over 1–2 seconds via a large, proximal peripheral vein, followed immediately by a rapid 5–10 mL 0.9% normal saline flush.
     • If no conversion within 1–2 minutes: Administer second dose of 0.2 mg/kg (maximum second dose 12 mg) rapid flush.
   • Electrical Cardioversion (if signs of shock, altered sensorium, or adenosine failure):
     • Synchronized cardioversion at 0.5 to 1 J/kg; increase to 2 J/kg if initial attempt is unsuccessful.
4. Shockable Arrhythmias and Energy Dose:
   • Pulseless Ventricular Tachycardia (pVT) and Ventricular Fibrillation (VF).
   • Initial defibrillation dose: 2 J/kg (unsynchronized biphasic shock), followed by 4 J/kg for subsequent shocks if refractory.

graph TD
    A[Infant with SVT: Narrow QRS, HR >220 bpm] --> B{Hemodynamically Stable?}
    B -- Yes --> C[Apply Ice Bag to Midface 10-15s]
    C --> D{Restoration of Sinus Rhythm?}
    D -- No --> E[IV/IO Adenosine: 0.1 mg/kg rapid push + flush]
    E --> F{Sinus Rhythm?}
    F -- No --> G[Repeat Adenosine: 0.2 mg/kg rapid push]
    B -- No / Decompensated --> H[Immediate Synchronized Cardioversion: 0.5 - 1 J/kg]
    G -- Refractory --> H
    H -- Refractory --> I[Increase to 2 J/kg; Consult Pediatric Cardiology]

1. Arrhythmia Identification and Characteristic Hallmark:
   • Diagnosis: Torsades de Pointes (TdP) / Polymorphic Ventricular Tachycardia associated with long QT.
   • Hallmark: Progressive, spindle-like shifting or twisting of the QRS axes and polarity around the isoelectric baseline, alternating every 5 to 15 beats, typically initiated by a ventricular premature beat interrupting the preceding prolonged T wave ("R-on-T" phenomenon) following a short-long-short R-R sequence.
2. Corrected QT Calculation (Bazett's Formula):
   $$ > \begin{aligned} > \text{QTc} &= \frac{\text{QT}}{\sqrt{\text{RR}}} \\ > &= \frac{0.52\text{ s}}{\sqrt{0.64\text{ s}}} = \frac{0.52}{0.80} \\ > &= \mathbf{0.65\text{ s}} \quad (\mathbf{650\text{ ms}}) > \end{aligned} > $$
   • Clinical Interpretation: Highly pathological. Normal upper limit of QTc is 440 ms in children (prolonged if >450 ms in males, >460 ms in females; QTc >500 ms carries high risk of malignant arrhythmias and sudden cardiac death).
3. Syndromic Association and Acquired Triggers:
   • Congenital Syndrome: Jervell and Lange-Nielsen Syndrome (autosomal recessive congenital Long QT Syndrome with bilateral sensorineural deafness; mutations in KCNQ1 or KCNE1).
   • Acquired triggers:
     • Electrolyte disturbances: Hypokalemia, hypomagnesemia, hypocalcemia.
     • Pharmacologic agents: Macrolides (azithromycin, erythromycin), antiemetics (ondansetron), psychotropics (haloperidol, tricyclics), class IA and III antiarrhythmics (procainamide, sotalol, amiodarone).
     • Physiological: Severe bradycardia or complete heart block.
4. Acute Management Protocol:
   • Pharmacological Stabilization:
     • Intravenous Magnesium Sulfate: 25–50 mg/kg (maximum single dose 2 g) IV/IO infused over 10–15 minutes, irrespective of the baseline serum magnesium concentration.
     • Serum Potassium Correction: Maintain high-normal serum potassium (4.5–5.0 mEq/L).
     • Heart rate stabilization: Overdrive atrial/ventricular pacing or low-dose Isoproterenol infusion (0.05–0.1 mcg/kg/min) to shorten the QT interval (contraindicated in congenital LQTS type 1 and 2, reserved for acquired pause-dependent TdP).
   • Hemodynamically Unstable / Pulseless Paroxysm:
     • Immediate Unsynchronized Defibrillation at 2 to 4 J/kg (synchronization is technically impossible due to the constantly shifting QRS amplitude and peak morphology, risking failed shock delivery).

1. Rhythm Identification:
   • Ventricular Bigeminy (alternating normal sinus complex followed by a premature ventricular complex [PVC]).
2. Differentiating Electrophysiologic Criteria:
   • Preceding Atrial Activity: Ventricular ectopic beats are not preceded by a premature ectopic P wave; aberrantly conducted supraventricular ectopics are preceded by a premature (often ectopic or inverted) P wave.
   • Compensatory Pause: Ventricular premature complexes typically demonstrate a complete compensatory pause (the interval between the normal beat preceding the PVC and the normal beat following it equals exactly two normal sinus cycles [2 × P-P]). Aberrantly conducted atrial beats show an incomplete compensatory pause.
   • QRS Morphology and ST-T Wave Axis: Ventricular ectopics exhibit marked widening (>0.09 seconds in children <10 years), bizarre multi-notched morphology, and secondary ST-T changes opposite (discordant) to the primary QRS deflection. Aberrancy typically exhibits classic right or left bundle branch block patterns (e.g., rSR' in V1) without axis shift.
3. Reversible Toxic, Metabolic, and Mechanical Triggers:
   • Electrolyte Derangements: Hypokalemia, hypomagnesemia, and hyperkalemia.
   • Pharmacological / Toxic: Digoxin toxicity, proarrhythmic effects of inotropes/inodilators (epinephrine, dopamine, milrinone), and tricyclic antidepressant ingestion.
   • Hypoxemia and Acid-Base Imbalances: Severe tissue hypoxia, respiratory acidosis, or severe metabolic acidosis.
   • Mechanical Irritation: Central venous catheter or temporary pacing wire irritating the right ventricular endocardium.
4. Therapeutic Approach:
   • Asymptomatic / Hemodynamically Compensated Patient:
     • Avoid empiric suppression with antiarrhythmics.
     • Identify and correct underlying triggers: normalize serum electrolytes (target K⁺ >4.0–4.5 mEq/L, Mg²⁺ >2.0 mg/dL), correct hypoxemia, reduce or wean proarrhythmic inotropes (e.g., milrinone), and verify catheter tip position away from the ventricular myocardium.
   • Hemodynamically Compromised or Clinically Symptomatic Patient:
     • First-line agent: Intravenous Lidocaine (Class IB) bolus of 1 mg/kg IV/IO over 2–3 minutes, followed by a continuous infusion of 20 to 50 mcg/kg/min.
     • Alternative agent: Intravenous Amiodarone 5 mg/kg administered over 20 to 60 minutes if ventricular ectopy leads to sustained runs of nonsustained or sustained ventricular tachycardia.

1. Clinical Syndrome and Electroencephalographic Characteristics:
   • Diagnosis: West Syndrome (Infantile Epileptic Spasms Syndrome / IESS).
   • Interictal EEG Pattern: Hypsarrhythmia.
   • Cardinal EEG Features:
     • High-voltage background (>200–300 microvolts), markedly disorganized and chaotic.
     • Multifocal, asynchronous, multidirectional spikes, sharp waves, and spike-and-wave discharges across all cerebral regions.
     • Marked loss of normal background rhythms with absent interhemispheric synchrony and intermittent generalized electrodecremental responses (voltage attenuation following bursts or during clinical spasms).
2. Classic Clinical Triad:
   • Infantile spasms (epileptic spasms occurring in clusters).
   • Hypsarrhythmia on interictal electroencephalogram.
   • Neurodevelopmental arrest or regression.
3. Most Common Etiology:
   • Hypoxic-Ischemic Encephalopathy (perinatal asphyxia) and perinatal stroke/encephalomalacia (structural-acquired etiology).
4. First-Line Pharmacotherapeutic Regimens:
   • Non-Tuberous Sclerosis Complex Cases (Hormonal Therapy is first-line):
     • Adrenocorticotropic Hormone (ACTH): High-dose protocol: 75 IU/m² intramuscularly twice daily (total 150 IU/m²/day) for 2 weeks, followed by a taper over 2 to 4 weeks. (Alternative low-dose protocol: 20–30 IU/day IM for 2 weeks, followed by taper).
     • Or High-Dose Oral Prednisolone: 4 mg/kg/day (maximum 60 mg/day) divided three to four times daily for 2 weeks; if spasm-free and hypsarrhythmia resolves at day 14, taper over 2 to 4 weeks.
   • Tuberous Sclerosis Complex (TSC) Associated Cases:
     • Vigabatrin (oral): Initial dose of 50 mg/kg/day orally divided twice daily, escalated rapidly over 7 days to 100–150 mg/kg/day. Continue for a minimum of 6 months if effective; monitor with baseline and periodic visual field / electroretinogram testing due to risk of permanent peripheral retinal field constriction.

Early cessation of epileptic spasms and electroencephalographic resolution of hypsarrhythmia within 14 days of treatment initiation correlates strongly with long-term neurocognitive preservation. First-line therapy must never be delayed with non-standard anti-seizure medications such as levetiracetam, valproate, or phenobarbital. Monitoring during hormonal therapy requires screening for hypertension, glycosuria, electrolyte imbalances, and severe infections.